Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now displays a 403 Forbidden error page, blocking access to the study record content. The additions include the 403 message and standard site header/footer, indicating restricted access to the content.SummaryDifference20%

- Check39 days agoChange DetectedThe page revision tag was updated from v3.6.5 to v3.6.6, indicating a minor page version update rather than substantive content changes.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page revision tag was updated from v3.6.4 to v3.6.5, signaling a new build of the study page. No changes to the study details or displayed information are evident.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page shows an updated revision tag to Revision: v3.6.4, reflecting an internal update to the study record. There is no indication of changes to trial content or data in this update.SummaryDifference0.0%

- Check97 days agoChange DetectedThe page shows a software revision from v3.6.2 to v3.6.3, indicating a routine site update.SummaryDifference0.0%

- Check104 days agoChange DetectedA new page revision (v3.6.2) was added, replacing the previous version (v3.6.0); this appears to be a deployment or formatting update rather than a substantive change to the study details.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.